Regulation of pericellular proteolysis by hepatocyte growth factor activator inhibitor type 1 (HAI-1) in trophoblast cells

Human Cell

Volumn 25, Issue 4, 2012, Pages 100-110

  Kohama, Kazuyo ^a   Kawaguchi, Makiko ^a   Fukushima, Tsuyoshi ^a   Lin, Chen Yong ^b   Kataoka, Hiroaki ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HAI 1; Laminin; Matriptase; Prostasin; Trophoblast

Indexed keywords

BETA ACTIN; HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR TYPE 1; LAMININ; MATRIPTASE; PROSTASIN; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL SURFACE; CHORIOCARCINOMA; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PLACENTA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TROPHOBLAST; WILD TYPE;

EID: 84872668758     PISSN: 09147470     EISSN: 17490774     Source Type: Journal    
DOI: 10.1007/s13577-012-0055-2     Document Type: Article

References (37)

1. Shimomura T, Denda K, Kitamura A, et al. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem. 1997; 272: 6370-6.
2. Eigenbrot C, Ganesan R, Kirchhofer D. Hepatocyte growth factor activator (HGFA): molecular structure and interactions with HGFA inhibtor-1 (HAI-1). FEBS J. 2010; 277: 2215-22.
3. Kataoka H, Kawaguchi M. Hepatocyte growth factor activator (HGFA): pathophysiological functions in vivo. FEBS J. 2010; 277: 2230-7.
4. Kawaguchi T, Qui L, Shimomura T, et al. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. J Biol Chem. 1997; 272: 27558-64.
5. Fukushima T, Kawaguchi M, Yamasaki M, Tanaka H, Yorita K, Kataoka H. Hepatocyte growth factor activator inhibitor type 1 suppresses metastatic pulmonary colonization of pancreatic carcinoma cells. Cancer Sci. 2011; 102: 407-13.
6. Kataoka H, Suganuma T, Shimomura T, et al. Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues. Cellular surface localization of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues. J Histochem Cytochem. 1999; 47: 673-82.
7. Kataoka H, Meng JY, Itoh H, et al. Localization of hepatocyte growth factor activator inhibitor type 1 in Langhans' cells of human placenta. Histochem Cell Biol. 2000; 114: 469-75.
8. Tanaka H, Fukushima T, Yorita K, Kawaguchi M, Kataoka H. Tissue injury alters the site of expression of hepatocyte growth factor activator inhibitor type 1 in bronchial epithelial cells. Hum Cell. 2009; 22: 11-7.
9. Tanaka H, Nagaike K, Takeda N, et al. Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is required for branching morphogenesis in the chorioallantoic placenta. Mol Cell Biol. 2005; 25: 5687-98.
10. Nagaike K, Kawaguchi M, Takeda N, et al. Defect of hepatocyte growth factor activator inhibitor type 1/serine protease inhibitor, Kunitz type 1 (Hai-1/Spint1) leads to ichthyosis-like condition and abnormal hair development in mice. Am J Pathol. 2008; 173: 1464-75.
11. Kawaguchi M, Takeda N, Hoshiko S, et al. Membrane-bound serine protease inhibitor HAI-1 is required for maintenance of intestinal epithelial integrity. Am J Pathol. 2011; 179: 1815-26.
12. Delaria KA, Muller DK, Marlor CW, et al. Characterization of placental bikunin, a novel human serine protease inhibitor. J Biol Chem. 1997; 272: 12209-14.
13. Fan B, Brennan J, Grant D, Peale F, Rangell L, Kirchhofer D. Hepatocyte growth factor activator inhibitor-1 (HAI-1) is essential for the integrity of basement membranes in the developing placental labyrinth. Dev Biol. 2007; 303: 222-30.
14. Szabo R, Molinolo A, List K, Bugge TH. Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development. Oncogene. 2007; 26: 1546-56.
15. Antalis TM, Buzza MS, Hodge KM, Hopper JD, Netzel-Arnett S. The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment. Biochem J. 2010; 428: 325-46.
16. Chen YW, Eckert RD, Johnson MD, Lin CY. The transmembrane serine protease matriptase: implications for cellular biology and human diseases. J Med Sci. 2012; 32: 97-108.
17. Satomi S, Yamasaki Y, Tsuzuki S, Hitomi Y, Iwanaga T, Fushiki T. A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover. Biochem Biophys Res Commun. 2001; 287: 995-1002.
18. Hurst NJ Jr, Najy AJ, Ustach CV, Movilla L, Kim HR. Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implication for breast cancer progression. Biochem J. 2012; 441: 909-18.
19. Ustach CV, Huamng W, Conley-LaComb MK, et al. A novel signaling axis of matriptase/PDGF-D/b-PDGFR in human prostate cancer. Cancer Res. 2010; 70: 9631-40.
20. List K, Currie B, Scharschmidt TC, et al. Autosomal ichthyosis with hypotrichosis syndrome displays low matriptase proteolytic activity and is phenocopied in ST14 hypomorphic mice. J Biol Chem. 2007; 282: 36714-23.
21. Miller GS, List K. The matriptase-prostasin proteolytic cascade in epithelial development and pathology. Cell Tissue Res. 2012;. doi: 10. 1007/s00441-012-1348-1.
22. Donaldson SH, Hirsh A, Li DC, et al. Regulation of the epithelial sodium channel by serine proteases in human airways. J Biol Chem. 2002; 277: 8338-45.
23. Chen YW, Wang JK, Chou FP, et al. Regulation of the matriptase-prostasin cell surface proteolytic cascade by hepatocyte growth factor activator inhibitor-1 during epidermal differentiation. J Biol Chem. 2010; 285: 31755-62.
24. Xu H, Xu Z, Tseng IC, et al. Mechanisms for the control of matriptase activity in the absence of sufficient HAI-1. Am J Physiol Cell Physiol. 2012; 302: C453-62.
25. Oberst MD, Chen LY, Kiyomiya K, et al. HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease. Am J Physiol Cell Physiol. 2005; 289: C462-70.
26. Lee MS, Tseng IC, Wang Y, et al. Autoactivation of matriptase in vitro: requirement for biomembrane and LDL receptor domain. Am J Physiol Cell Physiol. 2007; 293: C95-105.
27. Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B, Moran P. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett. 2005; 579: 1945-50.
28. Hashimoto T, Kato M, Shimomura T, Kitamura N. TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor. FEBS J. 2010; 277: 4888-900.
29. Kato M, Hashimoto T, Shimomura T, Kataoka H, Ohi H, Kitamura N. Hepatocyte growth factor activator inhibitor type 1 inhibits protease activity and proteolytic activation of human airway trypsin-like protease. J Biochem. 2012; 151: 179-87.
30. Fan B, Wu TD, Li W, Kirchhofer D. Identification of hepatocyte growth factor activator inhibitor-1B as a potential physiological inhibitor of prostasin. J Biol Chem. 2005; 280: 34513-20.
31. Pattillo RA, Gey GO. The establishment of a cell line of human hormone-synthesizing trophoblastic cells in vitro. Cancer Res. 1968; 28: 1231-6.
32. del Mónaco S, Assef Y, Kotsias BA. Epithelial sodium channel in a human trophoblast cell line (BeWo). J Membr Biol. 2008; 223: 127-39.
33. Tseng IC, Xu H, Chou FP, et al. Matriptase activation, an early cellular response to acidosis. J Biol Chem. 2010; 285: 3261-70.
34. Fukushima T, Tezuka T, Shimomura T, Nakano S, Kataoka H. Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem. 2007; 282: 18634-44.
35. Baba T, Kawaguchi M, Fukushima T, et al. Loss of membrane-bound serine protease inhibitor HAI-1 induces oral squamous cell carcinoma cells' invasiveness. J Pathol. 2012; 228: 181-92.
36. Szabo R. Uzzun Sales K, Kosa P, et al. Reduced prostasin (CAP1/PRSS8) activity eliminates HAI-1 and HAI-2 deficiency-associated developmental defects by preventing matriptase activation. PLoS Genet. 2012; 8: e1002937.
37. Friis S, Godiksen S, Bornholdt J, et al. Transport via the transcytotic pathway makes prostasin available as a substrate for matriptase. J Biol Chem. 2011; 286: 5793-802.